IGKV1D-22 and acute myeloid leukemia: IL6 is an essential driver of S100A8/A9 expression in acute myeloid leukemia cells via JAK/STAT3 signaling; and acute myeloid leukemia populations with elevated S100A8/A9 levels are highly resistant to doxorubicin, which can be efficiently reversed by blocking JAK/STAT3 signaling (Böttcher et al., 2022).